Octreotide and enterocutaneous fistula closure in neonates and children.

Abstract

UNLABELLED:

Enterocutaneous fistula and its conservative management still pose a challenge for the surgeon. The use of octreotide and somatostatin in neonates and children as adjunctive therapy in the conservative management of this condition, leads to major controversy regarding its efficacy. Therefore, we conducted an extensive literature review of published articles regarding the use of somatostatin and its analogues in the treatment of enterocutaneous fistula in neonates and children. Our review is then presented together with a case vignette and discusses the different practical aspects of the treatment with these drugs.

CONCLUSION:

The major diversity in treatment regimens among published studies makes outcomes difficult to compare. However, given the results of the different cases reported in the literature and of our own experience, we suggest a possible beneficial effect of octreotide and somatostatin on closure of enterocutaneous fistula in these patients.

• Authors: Noela Carrera-Guermeur, Rosa M Martín-Crespo, Hilda J Ramírez, Ángel Pantoja, Rafael Luque-Mialdea
• Journal: European journal of pediatrics (Eur J Pediatr) Vol. 175 Issue 3 Pg. 305-12 (Mar 2016) ISSN: 1432-1076 [Electronic] Germany
• PMID: 26811298 (Publication Type: Case Reports, Journal Article, Review)

Chemical References

• Gastrointestinal Agents
• Somatostatin
• Octreotide

Topics

• Child
• Child, Preschool
• Conservative Treatment
• Gastrointestinal Agents (adverse effects, therapeutic use)
• Humans
• Infant
• Infant, Newborn
• Infant, Premature
• Intestinal Fistula (drug therapy)
• Male
• Octreotide (adverse effects, therapeutic use)
• Somatostatin (adverse effects, therapeutic use)